Published in

Oxford University Press, American Journal of Health-System Pharmacy, 15(74), p. 1135-1141, 2017

DOI: 10.2146/ajhp160798

Taylor and Francis Group, Expert Opinion on Pharmacotherapy, 3(15), p. 429-436, 2014

DOI: 10.1517/14656566.2014.876007

Taylor and Francis Group, Expert Review of Respiratory Medicine, 5(15), p. 583-595, 2020

DOI: 10.1080/17476348.2021.1866990

Links

Tools

Export citation

Search in Google Scholar

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Journal article published in 2014 by Olivier Sitbon, Kamal Sharma, Nika Skoro-Sajer, Richard Channick, McLaughlin Vv, Léon Genecand, Kelly M. Chin, Chin Km, Aline Frey, Manuel Jonas Richter, Sean Gaine, Nazzareno Galiè, Ghofrani Ha, Henning Gall, Julie Wacker and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The endothelin (ET), nitric oxide (NO) and prostacyclin (PGI2) pathways are involved in pulmonary arterial hypertension (PAH) pathogenesis. While ET and NO are targeted early in the disease process, limitations of current pharmacotherapies that target the PGI2 pathway (PGI2 or PGI2 analogues) result in them not being used or delayed. Selexipag is a novel oral, selective agonist of the PGI2 (IP) receptor. Activation of the IP receptor induces vasodilation in the pulmonary circulation and inhibits the proliferation of vascular smooth muscle cells, key factors in PAH pathogenesis. By combining oral dosing with improved receptor selectivity, selexipag may enable earlier combination therapy targeting the three-molecular pathways of PAH with anticipated improvements in daily- and long-term clinical function and outcome in PAH.